New research reveals dual mechanisms behind Parkinson's disease: protein transport blockage and astrocyte disruption

New research reveals dual cellular mechanisms driving Parkinson's disease pathology. In neurons, toxic alpha-synuclein blocks the Sec61A protein gateway, preventing essential proteins from reaching lysosomes and causing waste-recycling failure. Meanwhile, the LRRK2-G2019S mutation disrupts the development of astrocytes, causing them to fail to mature and adopt a senescence-like phenotype that releases inflammatory molecules. These findings offer new therapeutic targets, including proteasome-enhancing drugs.

Alpha-synuclein protein transport blockage

• ▪Researchers from the Tofaris lab at the Kavli Institute for Nanoscience Discovery found that toxic forms of alpha-synuclein bind to the Sec61A protein, blocking a gateway that helps newly made proteins enter the endoplasmic reticulum.
• ▪The blockage of the endoplasmic reticulum gateway by alpha-synuclein inside neurons activates an alternative quality-control pathway known as UFMylation rather than the classical cellular stress response.

LRRK2-G2019S mutation effects

• ▪The Parkinson's disease-associated LRRK2-G2019S mutation increases the kinase activity of the LRRK2 enzyme, which is involved in cellular signaling and membrane trafficking.
• ▪A study published in npj Parkinson's Disease by Smits, Magni, Grzyb, and colleagues indicates that the LRRK2-G2019S mutation impairs the differentiation process of astrocytes.

Astrocyte development disruption

• ▪Disrupted astrocyte development and behavior caused by the LRRK2-G2019S mutation can create a self-reinforcing cycle of neural stress and inflammation, contributing to progressive damage in dopamine-producing neurons.
• ▪Immature neural cells carrying the LRRK2-G2019S mutation may fail to acquire the molecular and functional features of mature astrocytes, potentially reducing their ability to regulate synaptic signaling and support neurons.

Cellular senescence-like phenotype

• ▪Further studies are required to determine whether the senescence-like phenotype in astrocytes carrying the LRRK2-G2019S mutation occurs in living human brain tissue and whether it can be reversed.
• ▪Astrocytes carrying the LRRK2-G2019S mutation exhibit a senescence-like phenotype, a state where cells stop dividing and release a mixture of inflammatory signaling molecules, growth factors, and enzymes.

Lysosomal dysfunction mechanisms

• ▪Due to lysosomal failure, neurons release increased amounts of alpha-synuclein in tiny membrane-bound particles called extracellular vesicles, which can be detected in the bloodstream.
• ▪When the endoplasmic reticulum gateway is blocked by alpha-synuclein inside neurons, essential proteins fail to reach lysosomes, making lysosomes less effective at clearing unwanted proteins and cellular waste.

Proteasome enhancement therapeutic approaches

• ▪Enhancing the activity of the proteasome, the cell's main protein-clearance system, using drugs already approved for other medical conditions reversed protein transport defects in human neurons.
• ▪Researchers restored normal protein transport in human stem cell models of Parkinson's disease by lowering alpha-synuclein production using CRISPR interference.